Reports; Notices. (a) Unless MCC agrees otherwise in writing, MCA-Nepal will periodically provide to MCC, in form and substance satisfactory to MCC, the reports and information required by the Reporting Guidelines (each, a “Periodic Report”). MCA-Nepal will provide th...
(b) On October 30 of each year of the Compact Term (or within thirty (30) days of any written request by MCC), MCA-Nepal will provide to MCC an annual supplemental report containing the following information:
(i) the progress made by the Government toward achieving the Compact Goal and Project Objectives; (ii) additional information on accomplishments not presented in the Periodic Reports; (iii) developments in Compact implementation related to the consultative process, donor coordination, and lessons learned; and (iv) any report or document required to be delivered to MCC in connection with the Program under the MCC Environmental Guidelines (including the IFC Performance Standards that are incorporated by reference therein), any Audit Plan, or any Implementati...
(c) MCA-Nepal will furnish, or use its best efforts to furnish, to MCC an audit report in a form satisfactory to MCC for each audit required under the Compact, other than audits arranged for by MCC, no later than ninety (90) days after the end of the ...
(d) If at any time during the Compact Term, the Government materially reallocates or reduces the allocation in its national budget or any other governmental authority of Nepal at a departmental, municipal, regional, or other jurisdictional level mater...
(e) In addition to the Periodic Reports, MCA-Nepal will provide to MCC within thirty (30) days of a written request by MCC, or as otherwise agreed by MCC and MCA-Nepal in writing, such other reports, documents, or information as MCC may request from t...
(f) MCA-Nepal will submit the Periodic Reports and any other reports required hereunder electronically if requested by MCC or otherwise required by the Reporting Guidelines.
(g) MCA-Nepal will furnish MCC with a report, in form and substance satisfactory to MCC, by no later than March 31 of each calendar year regarding the Government’s contribution to the objectives of the Program required by Section 2.6(a) of the Compact...
Reports; Notices. All reports, notices, applications (including applications for instructions in accordance with Paragraph 8(f) hereof) and other communications required or permitted hereunder shall be in writing and shall be deemed given when addressed and delivered by facsimile transmission (confirmed by telephone call), which delivery may be followed by delivery by hand or overnight delivery service, to the address for the party set forth below or at such other address as a party may furnish by like notice to the other parties hereto: If to IMPSAT: IMPSAT Corporation Alfexxx Xxxexx 000 0000 Xxxxxx Xxxxx, Xxxxxxxxx Attn: Mr. Xxxxxxxxx Xxxxx, Vice President, Finance Facsimile Number: (582) 000-0000 With a copy to: Arnoxx & Xortxx 555 00xx Xxxxxx, X.X. Xxxxxxxxxx, X.X. 00000 Attn: Neil X. Xxxxxxx, Xxq. Facsimile Number: (202) 000-0000 If to the Exchange Agent: The Bank of New York 101 Xxxxxxx Xxxxxx Floor 21 West New York, New York 10286 Attn: Corporate Trust Administration Facsimile Number: (212) 000-0000 9 Delivery of a notice sent by facsimile transmission shall be deemed to be effective 24 hours after delivery has been confirmed by telephone.
Reports; Notices. Icagen shall furnish to CFF the following reports and/or notices:
(i) As soon as practicable, and in any event within [***] after the end of each calendar quarter (including the calendar quarter ending December 31), financial reports which describe the use of the Award Amount and the Matched Funds, the progress made toward achieving the purposes of the Research Plan, and the development of any Product in the event Icagen assumes responsibility for Development and Commercialization pursuant to Section 10.4, 10.8 or 10.7(a) pursuant to the [***], and any other information that CFF reasonably requests.
(ii) As soon as practicable after the Research Term, a closing report customary for a Research Plan at such stage of development which shall (A) be prepared by Icagen or an Icagen-approved Third Party, (B) be reasonably satisfactory to CFF, and (C) set forth Icagen’s final analysis, summary tables, data listings, results and conclusions from the Research Plan and such other information and materials as CFF may reasonably request.
(iii) As soon as practicable, and in any event within [***] after January 1 and June 1 of each fiscal year in the event Icagen assumes responsibility for Development and Commercialization pursuant to Section 10.4, 10.8 or 10.7(a) pursuant to the [***], progress reports and status updates on Icagen’s activities with respect to the Research Results and/or a Product including, without limitation, the Development and/or Commercialization, Icagen’s compliance with the terms of this Agreement, and any other information that CFF reasonably requests. Icagen shall include the requirements of this Section 3.2(d)(iii) in any agreements with sublicensees relating to the Development and/or Commercialization of any Products.
Reports; Notices. 13.1 All reports, notices, copies, requests, consents, approvals and other communication required or permitted to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed to have been properly given if hand delivered or sent by U.S. registered or certified mail, postage prepaid:
a. with respect to XXX: Ohio Department of Agriculture Office of Farmland Preservation 0000 X. Xxxx Xxxxxx Xxxxxxxxxxxx, Xxxx 00000-0000 Attn: Office of Farmland Preservation Telephone: 000-000-0000 b. with respect to Local Sponsor: Insert Local Sponsor/Agency Name Insert Local Sponsor/Agency Contact Insert Local Sponsor/Agency Address Insert Local Sponsor/Agency Phone Numbers
Reports; Notices. In addition to the reports described in Section 9.04, Equitable will send the Annuitant a report as of the end of each calendar year showing the status of the annuity and any other reports required by the Code or Treasury regulations.
Reports; Notices. AND SIGNS: Comply with federal, state or local law requiring delivery of reports or notices and/or posting of signs or notices.
Reports; Notices. Company shall with respect to the Research Program (x) maintain a system of accounting in accordance with GAAP, (y) keep full and complete financial records and maintain an effective system of internal controls, and (z) furnish to LLS the following reports and/or notices, all of which, for clarity, shall be Company’s Confidential Information:
(a) Company shall provide within [**] prior to each RAC meeting a progress report of the Research Program since the prior RAC meeting.
(b) Company shall provide within [**] after the end of each calendar year ending prior to the Research Termination Date and within [**] after the calendar quarter in which the Research Termination Date occurs, financial reports which describe the use of the Funding amounts and the Matched Funds (including, without limitation, a breakdown of the actual costs of the Research Program and how such Funding amounts and Matched Funds have been allocated and in fact used in respect of the Research Program), any Milestones achieved, and a summary of the development activities conducted with respect to Products under the Research Program during the applicable period covered by such report, together with such other summary information pertaining to activities in the Research Program during such period as LLS may reasonably request in writing, prior to preparation of such report, be included in such report.
(c) Within [**] after the Research Termination Date, a final progress report which shall (i) be prepared by Company or a Company-approved Third Party, and (ii) set forth a summary of the activities conducted in the Research Program and a summary of Company’s final analysis, summary tables, data listings, results and conclusions from the Research Program.
(d) As soon as practicable during the Research Program and thereafter, notice of any license, sublicense or transfer of any Research Program Invention, or permitted assignment by Company of this Agreement or its rights and/or obligations hereunder, or of any Change of Control Transaction (other than a Change of Control Transaction pursuant to the exercise of the Genentech Option).
(e) Notice of the exercise of the Genentech Option within [**] after such exercise.
(f) As soon as practicable, notice of all material actions, suits, claims, proceedings, investigations and inquiries that directly, or indirectly and materially, involve Company.
(g) Within [**] after [**] of each calendar year following the Research Termination Date until First Commer...
Reports; Notices. Sangamo shall (y) maintain a system of accounting in accordance with GAAP; and (z) furnish to JDRF the following reports and notices under the confidentiality provisions of Article V:
(a) As soon as practicable, and in any event within ninety (90) days after the end of each calendar quarter (including the calendar quarter ending December 31) prior to the Research Termination Date, a report describing (i) the actual costs of the Research Program during such quarter and how the Award Received and Matched Funds have been allocated and in fact used in respect of the Research Program, (ii) the Research Program work performed during such quarter, including, without limitation, Milestones achieved, (iii) a summary of all Research Program clinical data collected and analyzed during such quarter, (iv) a summary of all regulatory filings made during such calendar that materially alter the Research Plan, and (v) any other information that JDRF reasonably requests (each a “Quarterly Report”).
(b) As soon as practicable, and in any event within ninety (90) days after the end of the calendar quarter in which the Research Termination Date occurs or the termination of the Agreement becomes effective, whichever is earlier, a closing report which (i) sets forth Sangamo's final analysis, summary tables, data listings, results and conclusions from the Research Program and
Reports; Notices. (a) Endologix and its Subsidiaries shall (i) timely (without giving effect to any extensions pursuant to Rule 12b-25 of the Exchange Act) file all reports required to be filed with the SEC pursuant to the Exchange Act, and Endologix and its Subsidiaries shall not terminate the registration of the Common Stock under the Exchange Act or otherwise terminate its status as an issuer required to file reports under the Exchange Act, even if the securities laws would otherwise permit any such termination, and (ii) deliver to Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) a Compliance Certificate with each of its 10-Q and 10-K filings on the date such filings are made (or, if earlier, are required by the SEC to be made) with the SEC; provided that, with respect to clause (ii) only, solely to the extent any earnings or revenue report for the same period is publicly reported or is filed with the SEC prior to the time when any 10-Q or 10-K containing the applicable quarterly or annual financial statements is filed with the SEC and to the extent the earnings or revenue set forth in any such earnings or revenue report would result in a financial covenant default under Article VII, the Compliance Certificate shall instead be delivered by the Loan Parties to the Agent (and, during any Third Party Agent Retention Period, also the Third Party Agent) and the Lenders on the same day as such earnings or revenue report is publicly reported or is filed with the SEC. Each of such reports in clause (i) of the immediately preceding sentence will comply in all material respects with the applicable requirements of the Exchange Act and each of such reports and such Compliance Certificate will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The consolidated financial statements included in such reports will comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, will be prepared in accordance with GAAP, consistently applied (subject, in the case of unaudited quarterly financial statements, to normal year-end adjustments and lack of footnote disclosures), and will fairly present in all material respects the consolidated financial position of Endologix an...
Reports; Notices. (a) The books of account shall be closed promptly after the close of each calendar year, and the Managing General Partner shall prepare and send to each Partner:
(i) Within ninety (90) days after the end of the fiscal year, an Internal Revenue Service Schedule K-1 with respect to its distributive share of income, gains, deductions, losses and credits for income tax reporting purposes for each such fiscal year, together with any other information concerning the Partnership reasonably necessary for the preparation of a Partner's income tax return(s);
(ii) Within forty (40) days after the end of each of the first three (3) fiscal quarters, as of the last day of the fiscal quarter, a report containing unaudited financial statements of the Partnership and such other information as may be legally required or determined to be appropriate by the Managing General Partner; and
(iii) Within ninety (90) days after the end of the fiscal year, as of the close of the fiscal year, an annual report containing audited financial statements of the Partnership, presented in accordance with GAAP and certified by the Independent Accountants.
(b) Except during such periods as the Partnership shall be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Managing General Partner shall give prompt written notice to each other Partner upon (i) the effectiveness of any amendment to this agreement, (ii) the Managing General Partner's obtaining knowledge of any material default by the Partnership or a Person Controlled by the Partnership in respect of any financing secured by any Core Property or other material real property of the Partnership or any Person Controlled by the Partnership, (iii) the Managing General Partner's obtaining knowledge of any facts or circumstances that constitute a dissolution of the Partnership, (iv) the issuance of any amount of Class A Units or Additional Equity Interests (other than a de minimis amount), any
